SynsoryBio
"If-then" conditional logic for protein drugs
Cambridge, United States · Founded 2023
- Headquarters
- Cambridge, Massachusetts
- Employees
- 1–10
- Founded
- 2023
- Website
- synsorybio.com
- Last Round
- GrantApr 2024
- Rounds
- 2
About
SynsoryBio is creating next generation, protein therapeutics that sense where they are in the body and only activate at diseased tissue. This technology platform has the potential to expand the therapeutic window of highly potent drugs and apply to many diseases such as cancer and autoimmune disorders.
Summary
SynsoryBio is a Biotech company based in Cambridge, United States, founded in 2023. Its most recent funding was a Grant round in Apr 2024.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Apr 2024
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...